Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial

被引:0
|
作者
Mease, Philip J. [1 ,2 ]
Kavanaugh, Arthur [3 ]
Reimold, Andreas [4 ,5 ]
Tahir, Hasan [6 ]
Rech, Juergen [7 ]
Hall, Stephen [8 ]
Geusens, Piet [9 ,10 ]
Pascale, Pellet [11 ]
Delicha, Evie Maria [11 ]
Pricop, Luminita [12 ]
Mpofu, Shephard [11 ]
机构
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] UC San Diego Sch Med, La Jolla, CA USA
[4] Dallas VA Med Ctr, Dallas, TX USA
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[6] Barts Hlth NHS Trust, London, England
[7] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[8] Monash Univ, Melbourne, Vic, Australia
[9] Univ Hasselt, Hasselt, Belgium
[10] Maastricht Univ Hosp, Maastricht, Netherlands
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Pharmaceut, E Hanover, NJ USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
961
引用
收藏
页数:3
相关论文
共 50 条
  • [1] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
    Hall, S.
    Mease, P.
    Kavanaugh, A.
    Reimold, A.
    Tahir, H.
    Rech, J.
    Geusens, P.
    Pascale, P.
    Delicha, E.
    Pricop, L.
    Mpofu, S.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 37 - 38
  • [2] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL
    Mease, P. J.
    Kavanaugh, A.
    Reimold, A.
    Tahir, H.
    Rech, J.
    Hall, S.
    Geusens, P.
    Pascale, P.
    Delicha, E. M.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 952 - 953
  • [3] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM A PHASE 3 TRIAL
    McInnes, Iain B.
    Mease, Philip
    Ritchlin, Christopher T.
    Rahman, Proton
    Gottlieb, Alice B.
    Kirkham, Bruce
    RHEUMATOLOGY, 2017, 56 : 76 - 76
  • [4] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results from a Phase 3 Trial
    McInnes, Kin B.
    Mease, Philip J.
    Ritchlin, Christopher T.
    Rahman, Proton
    Gottlieb, Alice B.
    Kirkham, Bruce
    Kajekar, Radhika
    Delicha, Evie Maria
    Pricop, Luminita
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [5] Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial
    Mease, Philip J.
    Kavanaugh, Arthur
    Reimold, Andreas
    Tahir, Hasan
    Rech, Juergen
    Hall, Stephen
    Geusens, Piet
    Pascale, Pellet
    Delicha, Evie Maria
    Pricop, Luminita
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [6] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5 YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
    Mease, Philip J.
    Kavanaugh, Arthur
    Reimold, Andreas
    Tahir, Hasan
    Rech, Juergen
    Hall, Stephen
    Geusens, Piet
    Pellet, Pascale
    Delicha, Eumorphia Maria
    Pricop, Luminita
    Mpofu, Shephard
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 917 - 917
  • [7] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM A PHASE 3 TRIAL, FUTURE 2
    McInnes, I. B.
    Mease, P. J.
    Ritchlin, C.
    Rahman, P.
    Gottlieb, A.
    Kirkham, B.
    Kajekar, R.
    Delicha, E. M.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 145 - 145
  • [8] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5-YEAR EFFICACY AND SAFETY RESULTS FROM THE FUTURE 1 PHASE 3 TRIAL
    Tahir, Hasan
    Mease, Philip J.
    Kavanaugh, Arthur
    Reimold, Andreas
    Rech, Juergen
    Hall, Stephen
    Geusens, Piet
    Pellet, Pascale
    Delicha, Eumorphia Maria
    Pricop, Luminita
    Mpofu, Shephard
    RHEUMATOLOGY, 2019, 58 : 151 - 151
  • [9] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 FUTURE 2 STUDY
    Nash, P.
    McInnes, I. B.
    Rahman, P.
    Gottlieb, A. B.
    Kirkham, B.
    Ding, K.
    Pricop, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 379 - 379
  • [10] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 4-YEAR RESULTS FROM THE PHASE 3 FUTURE 2 STUDY
    McInnes, Iain B.
    Kirkham, Bruce
    Nash, Peter
    Rahman, Proton
    Gottlieb, Alice B.
    Ding, Kevin
    Pricop, Luminita
    RHEUMATOLOGY, 2019, 58